Outcome of end-stage renal disease in patients with rare causes of renal failure. I. Inherited and metabolic disorders.
This study represents the first national multi-center evaluation of treatment for end-stage renal disease outcome in patients with rare metabolic and inherited disorders in the United States. Because of the small number of such patients at single centers only a co-operative study could provide adequate data on enough patients for meaningful conclusions. By co-ordinating such data, the Network Forum provides a model for the newly organized U.S. Renal Data System and demonstrates the potential for useful special studies in the future. It is clear from these data that despite the systemic nature of these illnesses, treatment for ESRD can be applied to achieve excellent survival rates.
Nissenson
A R
AR
UCLA School of Medicine 90024.
Port
F K
FK
D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications* / Q000401:mortality; D003554:Cystinosis / Q000150:complications; D000795:Fabry Disease / Q000150:complications; D005260:Female; D006801:Humans; D006959:Hyperoxaluria / Q000150:complications; D007676:Kidney Failure, Chronic / Q000209:etiology* / Q000628:therapy; D016030:Kidney Transplantation; D008297:Male; D008661:Metabolism, Inborn Errors / Q000150:complications* / Q000401:mortality; D008875:Middle Aged; D011379:Prognosis; D006435:Renal Dialysis; D012737:Sex Factors